Refine
Year of publication
- 2021 (18) (remove)
Document Type
- Article (12)
- Doctoral Thesis (6)
Is part of the Bibliography
- no (18)
Keywords
- - (9)
- <i>Staphylococcus aureus</i> (2)
- COVID-19 (2)
- IgE (2)
- Immunoglobulin G (2)
- Immunoglobulin M (2)
- Methylene blue (2)
- Pathogen inactivation (2)
- Sepsis (2)
- Staphylococcus aureus (2)
- Th2 (2)
- vaccine (2)
- <i>Streptococcus mutans</i> (1)
- <i>Streptococcus oralis</i> (1)
- ATA (1)
- Airway inflammation (1)
- Allergen (1)
- Allergic diseases (1)
- Allergie (1)
- Allergy (1)
- Antikörper (1)
- Bacteria (1)
- Bacterial allergens (1)
- Blood compatibility test (1)
- CD38 antibody (1)
- Coombs test (1)
- Cystic fibrosis (1)
- Daratumumab (1)
- Donor research (1)
- Effects of blood donation (1)
- Gel card (1)
- GlpQ (1)
- Immune modulation (1)
- Immunmodulation (1)
- Immunreaktion (1)
- Indirect antiglobulin test (1)
- Inflammation (1)
- IsdB (1)
- JSNZ (1)
- LC-MS/MS (1)
- MRI (1)
- MSCRAMM (1)
- Mood regulation (1)
- PTMs (1)
- RBC antibody screening (1)
- Serine protease-like proteins (1)
- Solid phase (1)
- SplB (1)
- Staphylococci (1)
- Th2 cells (1)
- Therapeutic antibody interference (1)
- Western Blot Verfahren (1)
- adaptive Immunantwort (1)
- adhesion inhibitor (1)
- adjuvants (1)
- allergy (1)
- anti- (1)
- antibody repertoire (1)
- aurintricarboxylic acid (1)
- autoimmune (1)
- blood platelets (1)
- case report (1)
- cerebral thrombosis (1)
- colonization (1)
- complication (1)
- cystic fibrosis (1)
- haemorrhage (1)
- host-pathogen-interaction (1)
- immune polarization (1)
- immunoproteomics (1)
- infection (1)
- mass spectrometry (1)
- mouse (1)
- mouse models (1)
- multi-species biofilm (1)
- multiple myeloma (1)
- mupirocin (1)
- neutrophils (1)
- nose (1)
- phagocyte oxidase (1)
- phosphoproteomics (1)
- platelet transfusion proteomics (1)
- platelets (1)
- precision medicine (1)
- proteomic analysis (1)
- reactive oxygen species (1)
- signaling (1)
- sodium (1)
- targeted proteomics (1)
- thrombocytopenia (1)
- type 2 immune response (1)
Institute
- Institut für Immunologie u. Transfusionsmedizin - Abteilung Immunologie (18) (remove)
Publisher
- Frontiers Media S.A. (4)
- MDPI (4)
- S. Karger AG (3)
- BMJ Publishing Group (1)
: Platelets are components of the blood that are highly reactive, and they quickly respond
to multiple physiological and pathophysiological processes. In the last decade, it became clear that
platelets are the key components of circulation, linking hemostasis, innate, and acquired immunity.
Protein composition, localization, and activity are crucial for platelet function and regulation. The
current state of mass spectrometry-based proteomics has tremendous potential to identify and quantify thousands of proteins from a minimal amount of material, unravel multiple post-translational
modifications, and monitor platelet activity during drug treatments. This review focuses on the role
of proteomics in understanding the molecular basics of the classical and newly emerging functions
of platelets. including the recently described role of platelets in immunology and the development
of COVID-19.The state-of-the-art proteomic technologies and their application in studying platelet
biogenesis, signaling, and storage are described, and the potential of newly appeared trapped ion
mobility spectrometry (TIMS) is highlighted. Additionally, implementing proteomic methods in
platelet transfusion medicine, and as a diagnostic and prognostic tool, is discussed.
Our modern understanding of the hygiene hypothesis is that bacteria are not only the cause of disease but also essential for a healthy immune response and regulation. Varied microbial exposure prenatally and in early childhood protects us from pathological immune reactions such as autoimmune diseases and allergies. Against this background, the hypothesis that bacteria can act as allergens appears paradoxical. Nevertheless, there is growing evidence that Staphylococcus aureus (S. aureus) is associated with allergic reactions and serine protease-like proteins (Spls) produced by S. aureus have been identified as pacemakers of allergic reactions. To open prospects for treatment or causal therapy in patients at risk, the underlying mechanism of allergy induction by Spls was studied, focusing on the IL-33 pathway in airway inflammation. In a murine asthma model C57BL/6 J wild-type mice were repeatedly exposed to SplD via intratracheal application. After two weeks a Th2-biased inflammatory response was observed in the airways: IL-33 and eotaxin production, eosinophilia, bronchial hyperreactivity, and goblet cell hyperplasia. Blocking IL-33 activity with its soluble receptor ST2 counteracted these effects: significantly decreased numbers of eosinophils, IL-13+ type 2 ILCs, IL-13+CD4+ T cells as well as reduced IL-5 and IL-13 production by lymph node cells were observed. This study indicates that SplD induces allergic airway inflammation via the IL-33/ST2 axis. IL-33 upregulation was not accompanied by cell death, which indicates that IL-33 may not be passively released by dying cells but actively secreted by the airway epithelium. Future identification of the physiological substrates of the Spls may help to shed light on the source of IL-33 in SplD-induced airway inflammation.
While the causes of allergy induction by S. aureus Spls were addressed by investigating the underlying mechanism, the consequences of this were also of interest: Does the pro-allergenic response to S. aureus affect patients exposed to S. aureus in their airways? Therefore, the humoral and cellular immune response against Spls was studied in cystic fibrosis (CF) patients who are more frequently colonized with S. aureus than the healthy population and suffer from frequent recurrent airway infections. In this patient cohort a Th2 shift of the Spl-specific immune response became evident, including high Spl-specific serum IgE levels, strong induction of Th2 cell differentiation and production of type 2 cytokines following ex vivo stimulation with recombinant Spls. The observed response seems to be specific for Spls rather than being a general feature of S. aureus proteases since other putative allergens of S. aureus (ScpA, SspB) did not show increased IgE binding in CF sera. The Th2-driven immune response might impede antibacterial clearance and worsen the clinical picture. Larger clinical studies are needed to validate this notion by correlating the anti-S. aureus immune response with clinical parameters and testing new therapy options.
These results and findings shed light on a novel, possibly underestimated facet of the immune response against S. aureus and give impetus for further research on bacterial allergens in general, reaching beyond the species S. aureus.
Staphylococcus aureus (S. aureus) is among the most common infectious agents, burdening the
global health care system and challenging physicians. Thus, the demand for vaccination is
increasing, and despite many attempts, no vaccine is currently available. The iron-regulated
surface determinant protein B (IsdB) is a highly conserved surface protein of S. aureus. It has
an essential role in bacterial iron acquisition and cell attachment, functioning as a fitness factor.
It has been shown that IsdB is critical for S. aureus virulence and growth in iron-restricted
conditions, such as the human host. Therefore, IsdB was studied as a vaccine candidate. A nonadjuvant vaccine (V710) was developed based on IsdB, which showed promising results in the
preclinical, phase I, and phase IIa trials. Unexpectedly, in a phase IIb/III, in cardiothoracic
surgery patients that were infected by S. aureus, mortality was significantly higher in the
vaccinated group than the placebo. Despite increased antibody levels against IsdB in the
vaccinated patients, V710 failed to prevent S. aureus infection. Therefore, a better
understanding of the interaction between S. aureus and the immune system is required.
We have discovered that IsdB has an important role in host-pathogen interaction. This bacterial
protein activated human monocytes and murine bone marrow-derived dendritic cells
(mBMDCs) to produce proinflammatory cytokines, such as IL-6, TNF-α, IL-12, IL-23, IL-33,
and IL-1β. In silico molecular docking and DimPlot analysis predicted that IsdB binds to -TLR4
via non-covalent interactions. Microscale thermophoresis confirmed that IsdB has a high
affinity to recombinant human TLR4 in the nanomolar range. Inhibition of TLR4 completely
abolished the production of all the cytokines mentioned above in both cell types. Furthermore,
we characterized the TLR4 signaling pathway triggered by IsdB. In human monocytes, blocking
the myeloid differentiation factor 88 (MyD88) adaptor protein and NF-κβ transcription factor
caused complete abrogation of proinflammatory cytokines in response to IsdB, revealing that
IsdB induces cytokine release via the TLR4-MyD88-NF-κβ dependent pathway.
The consistent release of IL-1β suggested that IsdB induced activation of the inflammasome, a
multi-molecular complex known to play a crucial role in innate immunity. We corroborated our
observations in human monocytes and mBMDCs by inhibiting essential components of the
NLRP3 inflammasome. Blocking NLRP3, caspases in general and caspase-1 completely
inhibited the release of IL-1β. In monocytes, IsdB alone was sufficient to induce NLRPdependent IL-1β release, suggesting an alternative pathway of inflammasome activation. In
contrast, mBMDCs required an additional stimulus, such as ATP or MSU (known stress
signals) besides IsdB, to release IL-1β, indicating a classical inflammasome activation. These
results demonstrate that IsdB induces the release of IL-1β via the TLR4-NLRP3-Caspase-1
axis. Next, we addressed the molecular mechanisms involved in IsdB-induced IL-1β in monocytes.
A low concentration of intracellular potassium (K+) resulting from K+ efflux is known to trigger the NLRP3 inflammasome-mediated IL-1β release. We demonstrated that blocking potassium efflux by inhibition of ion channels, such as pannexin channels (P2X)7, and addition of extracellular KCl significantly reduced IsdB-induced IL-1β. Other common inflammasome activators, such as phagolysosome rupture and reactive oxygen species (ROS), did not contribute to the release of IL-1β in response to IsdB. In summary, we revealed yet another role of IsdB beyond iron acquisition from Hb and attachment to the host cells via vitronectin and integrins. It is conceivable that IsdB’s interaction with innate immune cells modulates the quality of the adaptive immune response, showing a new facet in the pathogen-host relationship of S. aureus that should be considered in future
vaccine development.
Protection against Staphylococcus aureus is determined by the polarization of the anti-bacterial immune effector mechanisms. Virulence factors of S. aureus can modulate these and induce differently polarized immune responses in a single individual. We proposed that this may be due to intrinsic properties of the bacterial proteins. To test this idea, we selected two virulence factors, the serine protease-like protein B (SplB) and the glycerophosphoryl diester phosphodiesterase (GlpQ). In humans naturally exposed to S. aureus, SplB induces a type 2-biased adaptive immune response, whereas GlpQ elicits type 1/type 3 immunity. We injected the recombinant bacterial antigens into the peritoneum of S. aureus-naïve C57BL/6N mice and analyzed the immune response. This was skewed by SplB toward a Th2 profile including specific IgE, whereas GlpQ was weakly immunogenic. To elucidate the influence of adjuvants on the proteins’ polarization potential, we studied Montanide ISA 71 VG and Imject™Alum, which promote a Th1 and Th2 response, respectively. Alum strongly increased antibody production to the Th2-polarizing protein SplB, but did not affect the response to GlpQ. Montanide enhanced the antibody production to both S. aureus virulence factors. Montanide also augmented the inflammation in general, whereas Alum had little effect on the cellular immune response. The adjuvants did not override the polarization potential of the S. aureus proteins on the adaptive immune response.
High Na+ Environments Impair Phagocyte Oxidase-Dependent Antibacterial Activity of Neutrophils
(2021)
Infection and inflammation can augment local Na+ abundance. These increases in local Na+ levels boost proinflammatory and antimicrobial macrophage activity and can favor polarization of T cells towards a proinflammatory Th17 phenotype. Although neutrophils play an important role in fighting intruding invaders, the impact of increased Na+ on the antimicrobial activity of neutrophils remains elusive. Here we show that, in neutrophils, increases in Na+ (high salt, HS) impair the ability of human and murine neutrophils to eliminate Escherichia coli and Staphylococcus aureus. High salt caused reduced spontaneous movement, degranulation and impaired production of reactive oxygen species (ROS) while leaving neutrophil viability unchanged. High salt enhanced the activity of the p38 mitogen-activated protein kinase (p38/MAPK) and increased the interleukin (IL)-8 release in a p38/MAPK-dependent manner. Whereas inhibition of p38/MAPK did not result in improved neutrophil defense, pharmacological blockade of the phagocyte oxidase (PHOX) or its genetic ablation mimicked the impaired antimicrobial activity detected under high salt conditions. Stimulation of neutrophils with phorbol-12-myristate-13-acetate (PMA) overcame high salt-induced impairment in ROS production and restored antimicrobial activity of neutrophils. Hence, we conclude that high salt-impaired PHOX activity results in diminished antimicrobial activity. Our findings suggest that increases in local Na+ represent an ionic checkpoint that prevents excessive ROS production of neutrophils, which decreases their antimicrobial potential and could potentially curtail ROS-mediated tissue damage.
Sepsis ist die dritthäufigste Todesursache in Deutschland und verursacht jährliche Krankenhauskosten von mehr als 8 Mrd. €. Über die Pathophysiologie ist noch immer vieles unbekannt. Bei der Bekämpfung von extrazellulären Infektionserregern spielt vor allem das humorale Immunsystem eine wichtige Rolle, da die von B-Zellen/ Plasmazellen gebildeten Antikörper wichtige antiinfektive Agenzien darstellen. Dennoch ist die Rolle der B-Zellen bei einer Sepsis nicht gut verstanden. Ergebnisse aus Mausmodellen, aber auch aus klinischen Studien mit Sepsispatienten zeigen einerseits die vermehrte Apoptose von B-Zellen, anderseits wurde auch eine polyklonale B-Zellaktivierung beschrieben, die mit einem unspezifischen Anstieg der Antikörperkonzentrationen im Blut einhergeht.
In dieser Arbeit sollte untersucht werden, ob während einer systemischen bakteriellen Infektion, wie der Sepsis, auch eine Erreger-spezifische Antikörperantwort ausgebildet wird. Mit Hilfe von zwei serologischen Assays wurde die Antikörperantwort von Sepsispatienten gegen extrazelluläre Proteine von 16 typischen Sepsiserregern bestimmt. Anhand von Plasmaproben aus zwei prospektiven Studien konnte die Antikörperkinetik von einem Zeitpunkt vor der klinischen Diagnose bis maximal 16 Tage nach Diagnose ermittelt werden.
Mittels eines Simple Western Assays - einem semi-quantitativen Immunoblot-Assay - wurde zunächst die Erreger-spezifische Antikörperantwort von Patienten mit einer vorliegenden mikrobiologischen Erregerdiagnose untersucht. 54 % der Patienten zeigten eine spezifische humorale Immunantwort gegen den mikrobiologisch diagnostizierten Erreger, wohingegen die Antikörperspiegel für das Kontrollantigen TT unverändert blieben.
Zur Untersuchung der zweiten Patientenkohorte wurde ein Bead-basierter Suspensions-Array auf Grundlage der xMAP-Technologie (Luminex®) entwickelt. Der Infection Array ermöglichte die gleichzeitige Quantifizierung der spezifischen Antikörperantwort gegen 16 verschiedene Erreger. Bei 64 der 76 untersuchten Patienten wurden Anstiege der IgG-Antikörper gegen einen oder mehrere dieser Erreger beobachtet. In 62,5 % der Fälle stimmten diese Anstiege mit der mikrobiologischen Diagnose überein. Bei 20/64 Patienten wurden signifikante Anstiege der IgG-Spiegel spezifisch für einen oder zwei Erreger nachgewiesen, in 44/64 Fällen wurden Anstiege gegen mehr als zwei Erreger beobachtet. Bei Letzteren richtete sich die Antikörperantwort hauptsächlich gegen Enterokokken und Enterobacteriaceae, was primär auf zwei Ursachen zurückgeführt werden kann: (i) Ein Großteil dieser Patienten hatte einen intraabdominellen Infektionsfokus. Polymikrobielle Infektionen durch endogene Darmbakterien, typischerweise verursacht durch eine Darmruptur oder die Insuffizienz einer chirurgischen Darmnaht, sind hierbei ein plausibler Befund, der der mikrobiologischen Diagnostik offenbar häufig entgeht. (ii) Außerdem können Sepsis-bedingte Organstörungen zu einer gesteigerten Darmpermeabilität führen, die wiederum die Translokation intestinaler Bakterien erleichtert.
Die Ergebnisse dieser Arbeit lassen den Schluss zu, dass die beobachteten Antikörperreaktionen auf eine Antigen-spezifische Memoryantwort zurückzuführen sind. In etwa 2/3 der Fälle wird eine Sepsis endogen durch Bakterien des eigenen Mikrobioms verursacht. Entsprechend war es nicht überraschend, dass gegen alle untersuchten Erreger bereits vor der Infektion und auch bei gesunden Kontrollpersonen basale antibakterielle IgG-Spiegel gemessen wurden. Zudem waren die IgG-Anstiege oft bereits zwischen Tag 0 und Tag 8 zu beobachten. Bei einer Primärantwort mit dem Erreger würde die Aktivierung der Zellen und der Klassenwechsel der Antikörper deutlich mehr Zeit erfordern.
Die Untersuchung der Erreger-spezifischen Antikörperantwort hat gezeigt, dass ein serologischer Assay Rückschlüsse auf den Infektionserreger zulässt. Außerdem zeigen die Daten, dass auch Kommensale wie Darmbakterien das Immunsystem prägen, was wiederum Einfluss auf die humorale Immunantwort während einer Infektion haben kann. Dieser Aspekt wird bei Mausmodellen oft vernachlässigt, kann aber entscheidend für die Translation der Ergebnisse aus Tierversuchen auf den Menschen sein. Aber auch diagnostisch bietet der Infection Array Einsatzmöglichkeiten. Im Gegensatz zur konventionellen Erregerdiagnostik ist die Serologie robust gegenüber einer bereits begonnenen Antibiotikagabe, und sie könnte dabei helfen, zwischen einer Kontamination und dem Infektionserreger zu unterscheiden, z. B. im Fall von KNS wie S. epidermidis. Ebenso wäre der Einsatz bei Biofilm-assoziierten Infektionen wie z. B. Protheseninfektionen oder Endokarditis denkbar. Hier besteht die Infektion oft bereits lange asymptomatisch, bevor sie klinisch diagnostiziert wird. Bei Diagnose bestehen meist bereits erhöhte Antikörperspiegel, die sich von denen gesunder Individuen unterscheiden. Ein serologischer Test könnte hier invasive Eingriffe, um an Material für die mikrobiologische Diagnose heranzukommen, reduzieren und die Sensitivität der Erregerdiagnostik erhöhen. Durch den Einsatz rekombinanter Proteine kann die Spezifität des Assays in der Zukunft erhöht werden. Zu diesem Zweck wurden in dieser Arbeit bereits erste immunogene Proteine identifiziert. Durch die Verwendung rekombinanter Proteine wäre zudem zukünftig die Erweiterung des Erregerpanels um typische, aber womöglich schwerkultivierbare Erreger möglich. Damit könnte die Sepsisforschung Neuland betreten.
Therapeutische Antikörper können unerwartete Wirkungen verursachen, wenn das Zielantigen nicht nur auf den Zielzellen exprimiert wird. Ein gegen das CD38-Antigen gerichteter Antikörper, Daratumumab (DARA), wurde für die Behandlung des multiplen Myeloms entwickelt. Allerdings beeinträchtigt dieser Antikörper erheblich die Verträglichkeitsuntersuchungen zwischen Blutkonserve und Patientenplasma vor der Transfusion von Erythrozytenkonzentraten.
CD38 wird auch auf Erythrozyten (RBCs) exprimiert. Durch die Bindung von DARA an die Spendererythrozyten wird im indirekten Antihumanglobulintest (IAT) eine in vitro Unverträglichkeit mit allen Testerythrozyten angezeigt. Dies wird dadurch verursacht, dass das erforderliche Antihumanglubulin (AHG) humanes IgG bindet, unabhängig davon, welches Zielantigen dieser Antikörper hat. Infolgedessen können Agglutinationen durch transfusionsrelevante Antikörper im Patientenplasma von DARA-induzieretn Agglutinationen nicht unterschieden werden, wodurch das Risiko für akute hämolytische Transfusionsreaktionen steigt.
Daraus ergab sich die Fragestellung für meine Arbeit – eine Modifikation für den IAT zu finden, der diese Interferenz auflöst. Ich habe zwei neue Strategien verfolgt: i) die Adsorption von DARA aus dem Patientenplasma mit CD38-exprimierenden peripheren Blutzellen, ii) die Blockung der DARA-Bindungsstelle auf Erythrozyten, ohne dass die Bindung von transfusionsrelevanten erythrozytären Antikörpern behindert wird.
Für den ersten Ansatz konnte ich PBMCs als die Zellen identifizieren, die die höchste CD38 Expression zeigten. Leider konnte die Inkubation von DARA-gespiktem Plasma selbst nach mehreren Adsorptionsschritten die Interferenz im IAT nicht vollständig beseitigen. Auch die Durchführung der Methode erwies sich als nicht praktikabel für ein Routine-Diagnostiklabor. Für den zweiten Ansatz habe ich mit Hilfe von Pepsin F(ab‘)2 Fragmente von DARA hergestellt um damit die DARA-Bindungsstelle auf den Erythrozyten zu blockieren, damit das AHG nur an gebundene transfusionsrelevante Antikörper bindet. Die Zugabe von DARA F(ab´)2 Fragmenten zu den Testerythrozyten konnte die DARA-induzierten Agglutinationen im IAT verhindern und im Plasma vorhandene erythrozytäre Alloantikörper sichtbar und differenzierbar machen. Weiterhin konnte ich nachweisen, dass die Zugabe von DARA (Fab´)2 Fragmenten nicht die Sensitivität der Teste im Gelzentrifugationstest und im Capture® beeinträchtigt. Experimente mit Plasma von Myelom-Patienten vor und nach der DARA-Infusion bestätigten die Ergebnisse. Die Verwendung von F(ab‘)2 Fragmenten ist ein vielversprechendes Verfahren, um Interferenzen von therapeutischen Antikörpern im IAT der prätransfusionellen Diagnostik aufzulösen - nicht nur für Daratumumab.
Introduction: In the light of the ongoing SARS-CoV-2 pandemic, convalescent plasma is a treatment option for COVID-19. In contrast to usual therapeutic plasma, the therapeutic agents of convalescent plasma do not represent clotting factor activities, but immunoglobulins. Quarantine storage of convalescent plasma as a measure to reduce the risk of pathogen transmission is not feasible. Therefore, pathogen inactivation (e.g., Theraflex®-MB, Macopharma, Mouvaux, France) is an attractive option. Data on the impact of pathogen inactivation by methylene blue (MB) treatment on antibody integrity are sparse. Methods: Antigen-specific binding capacity was tested before and after MB treatment of plasma (n = 10). IgG and IgM isoagglutinin titers were tested by agglutination in increasing dilutions. Furthermore, the binding of anti-EBV and anti-tetanus toxin IgG to their specific antigens was assessed by ELISA, and IgG binding to Fc receptors was assessed by flow cytometry using THP-1 cells expressing FcRI and FcRII. Results: There was no significant difference in the isoagglutinin titers, the antigen binding capacity of anti-EBV and anti-tetanus toxin IgG, as well as the Fc receptor binding capacity before and after MB treatment of plasma. Conclusion: MB treatment of plasma does not inhibit the binding capacity of IgM and IgG to their epitopes, or the Fc receptor interaction of IgG. Based on these results, MB treatment of convalescent plasma is appropriate to reduce the risk of pathogen transmission if quarantine storage is omitted.
ntroduction: In the light of the ongoing SARS-CoV-2 pandemic, convalescent plasma is a treatment option for COVID-19. In contrast to usual therapeutic plasma, the therapeutic agents of convalescent plasma do not represent clotting factor activities, but immunoglobulins. Quarantine storage of convalescent plasma as a measure to reduce the risk of pathogen transmission is not feasible. Therefore, pathogen inactivation (e.g., Theraflex®-MB, Macopharma, Mouvaux, France) is an attractive option. Data on the impact of pathogen inactivation by methylene blue (MB) treatment on antibody integrity are sparse. Methods: Antigen-specific binding capacity was tested before and after MB treatment of plasma (n = 10). IgG and IgM isoagglutinin titers were tested by agglutination in increasing dilutions. Furthermore, the binding of anti-EBV and anti-tetanus toxin IgG to their specific antigens was assessed by ELISA, and IgG binding to Fc receptors was assessed by flow cytometry using THP-1 cells expressing FcRI and FcRII. Results: There was no significant difference in the isoagglutinin titers, the antigen binding capacity of anti-EBV and anti-tetanus toxin IgG, as well as the Fc receptor binding capacity before and after MB treatment of plasma. Conclusion: MB treatment of plasma does not inhibit the binding capacity of IgM and IgG to their epitopes, or the Fc receptor interaction of IgG. Based on these results, MB treatment of convalescent plasma is appropriate to reduce the risk of pathogen transmission if quarantine storage is omitted.
Background and Objectives: Vaccine induced thrombotic thrombocytopenia (VITT) may occur after COVID-19 vaccination with recombinant adenoviral vector-based vaccines. VITT can present as cerebral sinus and venous thrombosis (CSVT), often complicated by intracranial hemorrhage. Today it is unclear, how long symptomatic VITT can persist. Here, we report the complicated long-term course of a VITT patient with extremely high titers of pathogenic anti-platelet factor 4 (PF4)-IgG antibodies. Methods: Clinical and laboratory findings are presented, including the course of platelet counts, D-Dimer levels, clinical presentation, imaging, SARS-CoV-2-serological and immunological, platelet activating anti-PF4-IgG, as well as autopsy findings. Results: The patient presented with extended superior sagittal sinus thrombosis with accompanying bifrontal intracerebral hemorrhage. Repeated treatment with intravenous immune globuline (IVIG) resolved recurrent episodes of thrombocytopenia. Moreover, the patient’s serum remained strongly positive for platelet-activating anti-PF4-IgG over three months. After a period of clinical stabilization, the patient suffered a recurrent and fatal intracranial hemorrhage. Conclusions: Complicated VITT with extremely high anti-PF4-IgG titers over three months can induce recurrent thrombocytopenia despite treatment with IVIG and anticoagulation. Plasma exchange, immunoadsorption, and /or immunosuppressive treatment may be considered in complicated VITT to reduce extraordinarily high levels of anti-PF4-IgG. Long-term therapy in such cases must take the individual bleeding risk and CSVT risk into account.
Sepsis wird als eine lebensbedrohliche Organdysfunktion aufgrund einer fehlregulierten Reaktion des Organismus auf eine Infektion definiert (Sepsis-3) (23). Trotz der Fortschritte in der modernen Medizintechnik und der Entwicklung neuer Medikamente bleibt die Sepsis weiterhin eine der häufigsten Todesursachen auf Intensivstationen weltweit. Hinzu kommt, dass zukünftig von einer steigenden Letalität auszugehen ist. Gründe hierfür sind neben dem zunehmenden Anteil älterer und chronisch kranker Patienten die zunehmende Invasivität vieler diagnostischer und operativer Eingriffe und die steigende Antibiotikaresistenz der Erreger (35). Der rasante Anstieg resistenter Krankheitserreger weltweit stellt die Sepsisbehandlung vor neue Herausforderungen. Entscheidend für die Senkung der Letalität ist eine schnelle Diagnostik und eine zielgerichtete Therapie. Die auf kulturellen Verfahren basierte vorherrschende mikrobiologische Standarddiagnostik ist zu zeitintensiv, daher werden aktuell molekular-basierte Verfahren entwickelt die eine schnelle Diagnostik ermöglichen.
Ziel dieser Arbeit war herauszufinden, ob sich der Organismus in einer Sepsis mit dem invasivem Krankheitserreger auseinandersetzt und eine humorale Immunantwort generiert und ob diese Immunantwort erregerspezifisch ist.
Zur Beantwortung dieser Fragen wurde in dieser Arbeit ein Verfahren entwickelt, um die Antikörper-Bindung an verschiedene bakterielle Proteine zu quantifizieren.
Dafür wurden humane Plasmen von Sepsispatienten aus einer prospektiven klinischen Studie (VYOO-Studie, Greifswald) mittels automatisiertem 1D-Western Blot Verfahren (Simple WesternTM assay) auf ihren erregerspezifischen Antikörper-Gehalt untersucht. Das Erregerspektrum wurde durch die extrazellulären Proteine häufiger Sepsiserreger
(Enterococcus faecium, Enterococcus faecalis, Staphylococcus haemolyticus, Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens und Escherichia coli) bereitgestellt. Alle Bakterienisolate, mit Ausnahme von S. aureus (USA300 Δspa), stammen aus Wundabstrichen, Trachealsekreten und Blutkulturen der Sepsispatienten und wurden in der Medizinischen Mikrobiologie des Greifswalder Universitätsklinikums aufbewahrt und für die Kultivierung zur Verfügung gestellt. Mit Hilfe des automatisierten, eindimensionalen Western Blot (1D-WB) wurde die Bindung der extrahierten extrazellulären Proteine (ec-stat) verschiedener Sepsiserreger an humanen Serumantikörpern untersucht.
Die Ergebnisse dieser Arbeit stellen heraus, dass immunkompetente Patienten während einer systemischen Infektion eine adaptive Immunantwort generieren. Um herauszufinden ob diese Immunantwort erregerspezifisch ist, wurden die Patientenplasmen nicht nur gegen extrazelluläre Proteine (ec-stat) des jeweiligen invasiven Erregers getestet, sondern auch gegen ec-stat anderer Bakterienspezies. Bei jedem der untersuchten Erreger konnten Patienten mit einem Antikörperanstieg identifiziert werden. Bei keinem Patienten stiegen Antikörper gegen alle untersuchten Erreger an. Schlussfolgernd beruht der Antikörperanstieg auf einer spezifischen Reaktion des Immunsystems auf bakterielle Invasion und ist demzufolge erregerspezifisch.
Es zeigte sich, dass v.a. bei Patienten mit einer abdominellen Sepsis die Antikörpertiter gegen mehrere Darmbakterienspezies ansteigen. Diese Befunde deuten darauf hin, dass sich das Immunsystem mit multiplen Erregern auseinandergesetzt hat, selbst wenn mikrobiologisch nur ein Erreger nachgewiesen wurde. Dies könnte relevant für die Antibiotikatherapie sein.
Des Weiteren konnte beobachtet werden, dass trotz mikrobiologisch nachgewiesenem Erreger bei einigen Patienten keine Immunantwort gegen den Keim generiert wurde.
Insgesamt zeigen die Daten, dass viele Patienten bereits vor einer Infektion spezifische Antikörper gebildet haben. Schlussfolgernd hat sich das adaptive Immunsystem schon seit längerer Zeit (vor Infektion) mit dem Krankheitserreger auseinander gesetzt.
Mit Hilfe einer immunologischen Sepsisserologie, wie der Verwendung des in dieser Arbeit genutzten Simple WesternTM Assays, lassen sich wichtige Informationen über die Pathogenese der Sepsis und die Reaktion des Immunsystems gewinnen. Diese ergänzen die konventionelle mikrobiologische Diagnostik. Ein besseres Verständnis der Immunantwort bei Sepsis ist eine Voraussetzung für die Entwicklung neuer therapeutische Ansätze. In wie weit der Simple WesternTM Assay - jedoch das diagnostische Portfolio bei Sepsis erweitern kann, müssen weitere Untersuchungen zur Sensitivität und Reproduzierbarkeit adressieren.
Vaccine-induced immune thrombotic thrombocytopenia (VITT) and cerebral venous sinus thrombosis (CVST) have been recently described as rare complications following vaccination against SARS-CoV-2 with vector vaccines. We report a case of a young woman who presented with VITT and cerebral CVST 7 days following vaccination with ChAdOx1 nCov-19 (AstraZeneca). While the initial MRI was considered void of pathological findings, MRI 3 days later revealed extensive CVST of the transversal and sigmoidal sinus with intracerebral haemorrhage. Diagnostic tests including a platelet-factor-4-induced platelet activation assay confirmed the diagnosis of VITT. Treatment with intravenous immunoglobulins and argatroban resulted in a normalisation of platelet counts and remission of CVST.
In cystic fibrosis (CF) infectious and allergic airway inflammation cause pulmonary exacerbations that destroy the lungs. Staphylococcus aureus is a common long-term colonizer and cause of recurrent airway infections in CF. The pathogen is also associated with respiratory allergy; especially the staphylococcal serine protease-like proteins (Spls) can induce type 2 immune responses in humans and mice. We measured the serum IgE levels specific to 7 proteases of S. aureus by ELISA, targeting 5 Spls (76 CF patients and 46 controls) and the staphopains A and B (16 CF patients and 46 controls). Then we compared cytokine release and phenotype of T cells that had been stimulated with Spls between 5 CF patients and 5 controls. CF patients had strongly increased serum IgE binding to all Spls but not to the staphopains. Compared to healthy controls, their Spl-stimulated T cells released more type 2 cytokines (IL-4, IL-5, IL-13) and more IL-6 with no difference in the secretion of type 1- or type 3 cytokines (IFNγ, IL-17A, IL-17F). IL-10 production was low in CF T cells. The phenotype of the Spl-exposed T cells shifted towards a Th2 or Th17 profile in CF but to a Th1 profile in controls. Sensitization to S. aureus Spls is common in CF. This discovery could explain episodes of allergic inflammation of hitherto unknown causation in CF and extend the diagnostic and therapeutic portfolio.
Humans are exposed to a plethora of microorganisms that reside on outer and inner body surfaces. These are collectively referred to as the human microbiome. The evolutionary relationship between humans and their microbiome is very complex. It is now widely accepted that these microorganisms are not just passive spectators but play an important role in health. The presence or absence of certain microbes is also linked to various diseases, including inflammatory bowel disease, cardiovascular disease, obesity, cancer, and allergies.
Allergies are several conditions caused by a misguided immune response to foreign antigens that are typically harmless. Common allergic diseases include atopic dermatitis (AD), allergic asthma, hay fever, and anaphylaxis. The incidences of allergic diseases are continuously rising, with up to 40% of the human population thought to be sensitised to environmental antigens. This increased incidence is not simply the result of societies becoming more aware and better at diagnosing these diseases. It is believed that the increases in allergies and sensitisation have environmental causes and are related to Western lifestyles. It is known that the rate of allergies is less frequent in developing countries. They are also more likely to occur in urban than rural areas. The prevailing view of the involvement of bacteria in allergies is described by the hygiene hypothesis. The hypothesis claims that decreased exposure to diverse microbial communities early in life increases the risk of developing allergic diseases. There are numerous examples to support this claim. For example, children born and raised in close contact to farm animals or in the presence of pets, and who are thus in direct and constant contact with a complex microbial environment, are protected from allergic diseases. On the other hand, colonisation or infection with certain bacteria increases allergic disease risks. This seems to contradict the hygiene hypothesis.
It appears that the members of the microbiome have different effects on allergy, and the hygiene hypothesis may not apply to every player in the complex microbial diversity that humans are in contact with. Therefore, a better understanding of the host bacterial interaction is required on the level of bacterial species.
This work studies the interplay between bacteria and the immune system to identify and characterise bacterial components with allergenic properties. In this quest, Staphylococcus aureus (S. aureus) and Staphylococcus epidermidis (S. epidermidis) were investigated for their allergenic properties and involvement in different allergic diseases. In the case of S. aureus, evidence is presented on allergic implications for two different components; serine protease-like proteins (Spls) and superantigens (SAg). Furthermore, experimental support is provided on the allergenic properties of the extracellular serine protease (Esp) from S. epidermidis. We argue that stimulating allergic reactions by staphylococci is an immune evasion mechanism that increases the survival chances of the bacteria within the host.
In chapter 1, an introduction is given to both S. aureus and S. epidermidis and their interactions with the immune system. Also, the bacterial components with allergenic properties and allergic diseases with known bacterial involvement are presented. Finally, the question of why bacteria cause allergy is discussed.
Chapter 2 describes allergic reactions to the Spls of S. aureus in a cohort of cystic fibrosis patients. Chapter 3 focuses on the SAgs of S. aureus. SAgs were discovered more than 30 years ago, but their physiological function is still under discussion. In this chapter, the allergenic properties of SAgs and their possible immunological mechanisms are reviewed, and a possible link between SAgs and allergic diseases is discussed. In chapter 4, the focus shifts to S. epidermidis and its involvement in AD. The human immune response to the Esp from S. epidermidis is characterised in healthy and AD individuals. The allergenic properties of Esp imply a detrimental role of S. epidermidis in AD. Finally, chapter 5 summarises and discusses the results of this thesis. In this section, the pieces are put together, and attention is brought back to the question of why bacteria cause allergies.
Background: Previous studies suggest that blood donation impacts blood donors’ psychological state, with either positive or negative effects, such as feeling more energetic or more exhausted. It has not yet been described how long these effects last. Materials and Methods: This prospective cohort study consisted of a qualitative and a quantitative part: (1) Psychological characteristics which changed after blood donation were identified by structured interviews of regular whole blood donors (n = 42). Based on this, a questionnaire addressing 7 psychological dimensions was established. (2) The psychological state of 100 blood donors was assessed after blood donation by applying the questionnaire 15–30 min before and during donation, as well as 15–30 min, 6 h, 24 h, 72 h, 1 week, and 8 weeks after donation. The resulting changes were summarized to a score. Furthermore, potential correlations of the score with pre-donation blood pressure, hemoglobin, or body mass index were calculated. Results: Seven items were identified which changed in at least 25% of blood donors (mood, concentration, satisfaction, resilience, spirit of initiative, physical well-being, energy level). In the 100 blood donors, the well-being score increased (positive effects, n = 23), showed minor changes (n = 53), or decreased (negative effects, n = 24). The positive effects lasted for about 1 week and the negative effects for 3 days. Conclusion: While the frequency of psychological effects following blood donation identified by our study was comparable to others, the changes of the psychological state in our donors were traceable for a longer period than previously acknowledged.
Our goal was to provide a comprehensive overview of the antibody response to Staphylococcus aureus antigens in the general population as a basis for defining disease-specific profiles and diagnostic signatures. We tested the specific IgG and IgA responses to 79 staphylococcal antigens in 996 individuals from the population-based Study of Health in Pomerania. Using a dilution-based multiplex suspension array, we extended the dynamic range of specific antibody detection to seven orders of magnitude, allowing the precise quantification of high and low abundant antibody specificities in the same sample. The observed IgG and IgA antibody responses were highly heterogeneous with differences between individuals as well as between bacterial antigens that spanned several orders of magnitude. Some antigens elicited significantly more IgG than IgA and vice versa. We confirmed a strong influence of colonization on the antibody response and quantified the influence of sex, smoking, age, body mass index, and serum glucose on anti-staphylococcal IgG and IgA. However, all host parameters tested explain only a small part of the extensive variability in individual response to the different antigens of S. aureus.